Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR OTCMKTS:CVSI NASDAQ:FBLG NYSE:NNVC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.68+0.9%$2.85$7.96▼$24.15$23.60M0.6315,685 shs87,582 shsCVSICV Sciences$0.03-0.3%$0.04$0.02▼$0.05$6.15M0.65205,859 shs23,025 shsFBLGFibroBiologics$0.54+0.7%$0.61$0.53▼$4.41$22.70M-0.73347,323 shs626,501 shsNNVCNanoViricides$1.44-1.7%$1.51$0.94▼$1.92$23.06M1.15233,680 shs93,389 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+0.43%+13.73%+73.78%+50.65%-72.86%CVSICV Sciences+1.21%-7.48%-12.57%+27.97%-27.23%FBLGFibroBiologics-5.46%-13.37%-7.57%-38.13%-79.30%NNVCNanoViricides+1.39%+4.29%-7.59%-3.95%-5.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$4.68+0.9%$2.85$7.96▼$24.15$23.60M0.6315,685 shs87,582 shsCVSICV Sciences$0.03-0.3%$0.04$0.02▼$0.05$6.15M0.65205,859 shs23,025 shsFBLGFibroBiologics$0.54+0.7%$0.61$0.53▼$4.41$22.70M-0.73347,323 shs626,501 shsNNVCNanoViricides$1.44-1.7%$1.51$0.94▼$1.92$23.06M1.15233,680 shs93,389 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+0.43%+13.73%+73.78%+50.65%-72.86%CVSICV Sciences+1.21%-7.48%-12.57%+27.97%-27.23%FBLGFibroBiologics-5.46%-13.37%-7.57%-38.13%-79.30%NNVCNanoViricides+1.39%+4.29%-7.59%-3.95%-5.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/ACVSICV Sciences 0.00N/AN/AN/AFBLGFibroBiologics 3.00Buy$13.002,298.52% UpsideNNVCNanoViricides 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CVSI, FBLG, NNVC, and ALVR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.008/5/2025FBLGFibroBiologicsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00 ➝ $12.008/4/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.007/29/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.007/9/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.006/17/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ACVSICV Sciences$15.70M0.39N/AN/A$0.01 per share3.33FBLGFibroBiologicsN/AN/AN/AN/A$0.08 per shareN/ANNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%11/10/2025 (Estimated)CVSICV Sciences-$2.39MN/A0.00∞N/A-10.36%-80.82%-19.38%N/AFBLGFibroBiologics-$11.16M-$0.36N/AN/AN/AN/A-710.25%-118.02%11/11/2025 (Estimated)NNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/ALatest CVSI, FBLG, NNVC, and ALVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2025Q1 2025FBLGFibroBiologics-$0.11-$0.12-$0.01-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/ACVSICV SciencesN/AN/AN/AN/AN/AFBLGFibroBiologicsN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78CVSICV Sciences0.121.040.30FBLGFibroBiologicsN/A0.930.93NNVCNanoViricidesN/A3.442.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%CVSICV SciencesN/AFBLGFibroBiologicsN/ANNVCNanoViricides10.30%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%CVSICV Sciences1.30%FBLGFibroBiologics20.80%NNVCNanoViricides4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableCVSICV Sciences70184.79 million182.39 millionNot OptionableFBLGFibroBiologics1041.89 million33.18 millionN/ANNVCNanoViricides2016.07 million14.92 millionOptionableCVSI, FBLG, NNVC, and ALVR HeadlinesRecent News About These CompaniesNanoViricides (NYSE:NNVC) Shares Up 1.4% - Time to Buy?September 10 at 3:18 AM | americanbankingnews.comNanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025September 9 at 8:30 AM | accessnewswire.comACEO Chat with Anil Diwan, President & Executive Chairman at NanoViricides, Inc.September 9 at 4:18 AM | finance.yahoo.comNanoViricides Reports NV-387’s Anti-Inflammatory Effects Could Combat Viral-Induced Cancer ResurgenceAugust 27, 2025 | theglobeandmail.comNanoViricides says broad-spectrum antiviral candidate NV-387 could address current, emerging and future COVID strainsAugust 27, 2025 | proactiveinvestors.comNanoViricides says antiviral NV-387 may reduce cancer resurgence risk tied to viral infectionsAugust 18, 2025 | proactiveinvestors.comA Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical TrialsAugust 18, 2025 | accessnewswire.comANanoViricides says antiviral candidate NV-387 could address global measles surgeJuly 30, 2025 | proactiveinvestors.comMeasles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricidesJuly 30, 2025 | accessnewswire.comANanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387July 23, 2025 | proactiveinvestors.comNanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive ValueJuly 23, 2025 | accessnewswire.comAMeasles Now Has a Drug – NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricidesJuly 21, 2025 | usatoday.comNanoViricides says lead antiviral boosted survival in measles-infected miceJuly 21, 2025 | proactiveinvestors.comMeasles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricidesJuly 21, 2025 | accessnewswire.comANanoViricides designs trial protocol for phase II MPox Clade Ia with a novel drug NV-387 for treating MPox diseaseJuly 18, 2025 | pharmabiz.comPWHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely, Says NanoViricidesJuly 16, 2025 | azcentral.comANanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergencyJuly 16, 2025 | proactiveinvestors.comWHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricidesJuly 16, 2025 | accessnewswire.comANanoViricides positioned at forefront of Mpox treatment efforts, says ZacksJuly 15, 2025 | proactiveinvestors.comNanoViricides positioned at forefront of Mpox treatment efforts, says ZacksJuly 15, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVSI, FBLG, NNVC, and ALVR Company DescriptionsAlloVir NASDAQ:ALVR$4.68 +0.04 (+0.86%) As of 09/9/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.CV Sciences OTCMKTS:CVSI$0.03 0.00 (-0.30%) As of 01:26 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.FibroBiologics NASDAQ:FBLG$0.54 +0.00 (+0.69%) Closing price 03:58 PM EasternExtended Trading$0.55 +0.00 (+0.55%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.NanoViricides NYSE:NNVC$1.44 -0.03 (-1.71%) Closing price 03:58 PM EasternExtended Trading$1.44 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Beyond DIY: Home Depot's Conquest of the Professional Market Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
